Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486895 · ClinicalTrials.gov registry record · Phase 1
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
A Phase 1 study of Healthy Adult Participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT07486895: Completed Phase 1 study of Healthy Adult Participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT07486895 is a Phase 1 study of Healthy Adult Participants that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 44 participants, below the 69-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07486895, a Phase 1 study of Healthy Adult Participants, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.
Conditions Studied
Interventions
- DRUG Centanafadine
Study Locations (1)
Kansas
- ICON plc - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 1 |
What the finished NCT07486895 record still lists
NCT07486895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 69-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 1 intervention - of which Centanafadine is the first listed.
NCT07486895 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT07486895 about?
NCT07486895 is a clinical study titled "Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects". The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult participants.
What is the current status of trial NCT07486895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-03-08. Estimated completion is 2023-05-18.
What conditions does trial NCT07486895 study?
This clinical trial studies the following conditions: Healthy Adult Participants.
What interventions are being tested in trial NCT07486895?
The interventions under investigation include: Centanafadine (DRUG).
Who is sponsoring clinical trial NCT07486895?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07486895 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
RECRUITING · Phase 1
-
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
RECRUITING · Phase 1
-
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI